Comparative Pharmacology
Head-to-head clinical analysis: EFFEXOR versus SAVELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFEXOR versus SAVELLA.
EFFEXOR vs SAVELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits serotonin and norepinephrine reuptake by blocking the serotonin transporter (SERT) and norepinephrine transporter (NET), increasing extracellular concentrations of serotonin and norepinephrine in the CNS.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); also weakly inhibits dopamine reuptake. Binds to serotonin and norepinephrine transporters, increasing their extracellular concentrations.
Initial: 75 mg/day PO in 2-3 divided doses; may increase by 75 mg/day increments at intervals of 4 days or more; max 375 mg/day. Extended-release: initial 37.5-75 mg PO once daily, titrate up to max 225 mg/day.
100 mg orally twice daily; may initiate at 50 mg twice daily and increase to 100 mg twice daily after 1 week.
None Documented
None Documented
Venlafaxine: ~5 ± 2 hours; ODV (active metabolite): ~11 ± 2 hours. At steady state, effective half-life for total active moiety (venlafaxine + ODV) is ~11 hours. Clinical context: requires twice-daily dosing for immediate-release; extended-release formulations allow once-daily dosing.
Approximately 11 hours for milnacipran (SAVELLA). In the context of twice-daily dosing, steady state is reached within 2-3 days.
Primarily renal (≈87% of dose eliminated in urine), with approximately 29% as unchanged venlafaxine, 26% as unconjugated O-desmethylvenlafaxine (ODV), and the remainder as other metabolites. Fecal elimination accounts for <10%. Biliary excretion is negligible.
Renal excretion of unchanged drug and metabolites accounts for approximately 51-58% of the dose. Fecal excretion accounts for about 19-22%. The remainder is eliminated via other routes (e.g., oxidative metabolism and subsequent conjugation).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant